jRCT2080224907招募中2 期
Phase I/II, Two-Part, Multicenter First-in-Human Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Subjects With Advanced Solid Malignant Tumors (IDeate-PanTumor01)
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 250
- 试验地点
- 1
- 主要终点
- Dose Escalation Part: safety and tolerability
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 干预模型
- Multi Center, Open-label
- 主要目的
- Treatment Purpose
入排标准
- 年龄范围
- 18age old over 至 No limit（—）
- 性别
- All
入选标准
- •Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or
- •Has at least 1 measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 on computed tomography (CT) or magnetic resonance imaging (MRI) as assessed by Investigator. Measurable lesions should not be from a previously irradiated site. If the lesion at a previously irradiated site is the only selectable target lesion, a radiological assessment showing significant progression of the irradiated lesion should be provided by the Investigator.
- •Has adequate cardiac, hematopoietic, renal and hepatic functions
- •Has an adequate treatment washout period prior to start of study treatment
- •Has a pathologically documented advanced/unresectable or metastatic head and neck squamous cell carcinoma, esophageal squamous cell carcinoma, squamous and adenocarcinoma non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), bladder cancer, sarcoma, endometrial cancer, melanoma, adenocarcinoma CRPC (primary neuroendocrine or histologically confirmed neuroendocrine differentiated prostate cancer is not allowed), breast cancer that is refractory to or intolerable with standard treatment, or for which no standard treatment is available.
- •For Expansion Cohort 4 2L Esophageal squamous cell carcinoma (ESCC) participants only:
- •Has disease progression a post platinum-based and an immune checkpoint inhibitor (ICI) treatment per global or local guidelines, with a maximum of one prior line of systemic therapy for unresectable advanced or metastatic ESCC.
排除标准
- •Has prior treatment with B7-H3 targeted agent, including I-DXd.
- •Has had prior discontinuation of an antibody drug conjugate (ADC) that consists of an exatecan derivative (e.g., trastuzumab deruxtecan) due to treatment-related toxicities.
- •Has multiple primary malignancies within 3 years, except adequately resected non-melanoma skin cancer, curatively treated in situ disease, superficial GI tract tumors and non-muscle invasive bladder cancer curatively resected by endoscopic surgery.
- •Uncontrolled significant cardiovascular disease
- •Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses including, but not limited to, any underlying pulmonary disorder, or any autoimmune, connective tissue or inflammatory disorders with potential pulmonary involvement, prior pneumonectomy, or requirement for supplemental oxygen
- •Has an uncontrolled infection requiring systemic therapy.
- •Has substance abuse or any other medical conditions that would increase the safety risk to the subject or interfere with participation of the subject or evaluation of the clinical study in the opinion of the Investigator.
结局指标
主要结局
Dose Escalation Part: safety and tolerability
To evaluate the safety and tolerability and to determine the maximum tolerated dose and the recommended dose for expansion of Ifinatamab Deruxtecan (I-DXd).
Dose Expansion Part: safety, tolerability and antitumor activity
To investigate the safety, tolerability and antitumor activity of I-DXd.
次要结局
- pharmacokinetics
- other
研究者
研究点 (1)
Loading locations...
相似试验
招募中
不适用
A Study of Ifinatamab Deruxtecan in Subjects with Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)jRCT2031240571Daiichi Sankyo Co., Ltd.510
招募中
不适用
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer (IDeate-Lung02)jRCT2031230631Daiichi Sankyo Co., Ltd.540
进行中（未招募）
不适用
Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)Extensive-stage Small Cell Lung CancerjRCT2041220019Daiichi Sankyo Co., Ltd.180
招募中
1 期
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)NCT06863272Merck Sharp & Dohme LLC360
招募中
3 期
A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)Esophageal Squamous Cell CarcinomaNCT06644781Daiichi Sankyo510